Yoshinobu Saito, Shinichi Sasaki, Katsunori Oikado, Junya Tominaga, Masafumi Sata, Fumikazu Sakai, Terufumi Kato, Tae Iwasawa, Hirotsugu Kenmotsu, Masahiko Kusumoto, Tomohisa Baba, Masahiro Endo, Yutaka Fujiwara, Hiroaki Sugiura, Noriyo Yanagawa, Yoshihiko Ito, Takahiko Sakamoto, Yuichiro Ohe, Kazuyoshi Kuwano
Nivolumab can cause interstitial lung disease (ILD), which may be fatal; however, mortality risk factors have not been identified. This post-marketing study evaluated the poor prognostic factors of ILD in nivolumab-treated patients with non-small cell lung cancer (NSCLC) in Japan. Clinical and chest imaging findings for each ILD case were assessed by an Expert Central Review Committee, and prognosis was evaluated by radiographic findings, including the presence/absence of peritumoral ground glass opacity (peritumoral-GGO)...
October 24, 2020: Cancer Science
Lu Liu, Qian Wang, Cen Xie, Ning Xi, Zitao Guo, Ming Li, Xiangyu Hou, Ningjie Xie, Mingming Sun, Jing Li, Xiaoyan Chen
AIMS: Ningetinib is a tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC). The present study aims to investigate the drug interaction of ningetinib and gefitinib and the mechanism of high plasma exposure of N-demethylated ningetinib (M1) in NSCLC patients. METHODS: Patients with NSCLC were recruited. Metabolism and transport assays were performed using in vitro models. Deuterated M1 was used to study the effects of ningetinib and gefitinib on M1 efflux in ICR mice...
October 24, 2020: British Journal of Clinical Pharmacology
Linzhi Han, Hongjie Shi, Yuan Luo, Wenjie Sun, Shuying Li, Nannan Zhang, Xueping Jiang, Yan Gong, Conghua Xie
Lung adenocarcinoma (LUAD) is the most common and lethal cancer worldwide. Radiotherapy (RT) is widely used at all stages of LUAD, and the development of immunotherapy substantially enhances the survival of LUAD patients. Although the emerging treatments for LUAD have improved prognosis, only a small fraction of patients can benefit from clinical therapies. Thereby, approaches assessing responses to RT and immunotherapy in LUAD patients are essential. After integrating the analysis of RT, immunization, mRNA, and clinical information, we constructed a signature based on 308 tumor-infiltrating B lymphocyte-specific genes (TILBSig) using a machine learning method...
October 24, 2020: Cancer Medicine
Craig A Bollig, Christopher I Newberry, Tabitha L I Galloway, Robert P Zitsch, Elyse K Hanly, Vivian L Zhu, Nitin Pagedar, Rohit Nallani, Andres M Bur, William C Spanos, Jeffrey B Jorgensen
OBJECTIVES/HYPOTHESIS: Investigate the relationship between site and pattern of distant metastasis (DM) and overall survival (OS) in a multi-institutional cohort of patients with DM head and neck cancer (HNC). STUDY DESIGN: Retrospective review. METHODS: 283 patients treated at 4 academic centers in the Midwest HNC Consortium between 2000 and 2015 were retrospectively reviewed. Disease patterns were divided between solitary metastatic versus polymetastatic (≥2 sites) disease...
October 24, 2020: Laryngoscope
Patricia J Hollen, Richard J Gralla, Ryan D Gentzler, Richard D Hall, Bethany Coyne, Haiying Cheng, Balazs Halmos, Jane Gildersleeve, Claudia Calderon, Ivora Hinton, Geoffrey Weiss, Jeffrey Crawford, Jane Cerise, Martin Lesser
BACKGROUND: Thousands of patients annually receive treatment for advanced NSCLC, but little is known about their views on the decision to receive that treatment, or regret. This trial prospectively evaluated the incidence of regret and whether baseline characteristics, patient decision-making parameters, or clinical progress early in the treatment course predicts regret. MATERIALS AND METHODS: Patients receiving systemic treatment for advanced NSCLC completed every 3-week PRO assessment using the electronic LCSS, including the 3-Item Global Index ("3-IGI," assessing overall distress, activities, and QL)...
October 23, 2020: Oncologist
Taichi Miyawaki, Kazushige Wakuda, Hirotsugu Kenmotsu, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Akira Ono, Tateaki Naito, Haruyasu Murakami, Akifumi Notsu, Keita Mori, Hideyuki Harada, Masahiro Endo, Yasuhisa Ohde, Kazuhisa Takahashi, Toshiaki Takahashi
Despite the importance of accurate disease definitions to effective management and treatment decisions, there is currently no consensus on what constitutes oligometastatic non-small-cell lung cancer (NSCLC). Predominant patterns of initial progressive disease (PD) after first-line systemic therapy have shown to be substantial basis for local ablative therapy (LAT) to all disease sites in patients with oligometastatic NSCLC, suggesting that these patterns could be helpful in defining synchronous oligometastatic NSCLC...
October 23, 2020: Cancer Science
Yi-Jing Cheng, Ching-Kai Lin, Chao-Yu Chen, Po-Chien Chien, Ho-Hsien Chuan, Chao-Chi Ho, Yun-Chien Cheng
This study compared effects of plasma-activated medium (PAM) with effects of conventional clinical thermal therapy on both lung cancer cells and benign cells for management of malignant pleural effusion (MPE). For MPE treatment, chemotherapy, photodynamic therapy, and thermal therapy are used but caused systemic side effects, patient photosensitivity, and edema, respectively. Recent studies show that plasma induces apoptosis in cancer cells with minor effects on normal cells and is cost-effective. However, the effects of plasma on MPE have not been investigated previously...
October 23, 2020: Scientific Reports
Ming-Jenn Chen, De-Wei Wu, Yao-Chen Wang, Chi-Yi Chen, Huei Lee
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
October 23, 2020: Scientific Reports
Cristina Pavan, Rosangela Santalucia, Riccardo Leinardi, Marco Fabbiani, Yousof Yakoub, Francine Uwambayinema, Piero Ugliengo, Maura Tomatis, Gianmario Martra, Francesco Turci, Dominique Lison, Bice Fubini
Inhalation of silica particles can induce inflammatory lung reactions that lead to silicosis and/or lung cancer when the particles are biopersistent. This toxic activity of silica dusts is extremely variable depending on their source and preparation methods. The exact molecular moiety that explains and predicts this variable toxicity of silica remains elusive. Here, we have identified a unique subfamily of silanols as the major determinant of silica particle toxicity. This population of "nearly free silanols" (NFS) appears on the surface of quartz particles upon fracture and can be modulated by thermal treatments...
October 23, 2020: Proceedings of the National Academy of Sciences of the United States of America
Anne-Laure Couderc, Pascale Tomasini, Dominique Rey, Emilie Nouguerède, Florian Correard, Fabrice Barlesi, Pascal Thomas, Patrick Villani, Laurent Greillier
BACKGROUND: Lung cancer affects older and older old adults and is the leading cause of death by cancer. Comprehensive Geriatric Assessment (CGA) is recommended before and during cancer treatment to guide therapy management in this population. METHODS: This study was conducted between September 2015 and January 2019 at Marseille University Hospital (AP-HM). During this period, all consecutive outpatients 70 years or older referred for a CGA before initiation of lung cancer treatment were enrolled...
October 20, 2020: Journal of Geriatric Oncology
David R Spigel, Robert M Jotte, Santiago Ponce Aix, Laurent Gressot, Daniel Morgensztern, Michael McCleod, Mark A Socinski, Davey Daniel, Oscar Juan-Vidal, Kathryn F Mileham, Howard West, Ray Page, Niels Reinmuth, Jeanna Knoble, Tianlei Chen, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Cesare Gridelli, Michael Thomas
BACKGROUND: We evaluated maintenance nanoparticle albumin-bound (nab) paclitaxel in the treatment of advanced squamous non-small-cell lung cancer. PATIENTS AND METHODS: Patients with treatment-naive squamous non-small-cell lung cancer received four 21-day cycles of nab-paclitaxel 100 mg/m2 on days 1, 8, 15 plus carboplatin area under the curve 6 on day 1 as induction therapy. Patients without disease progression after induction were randomized 2:1 to maintenance nab-paclitaxel 100 mg/m2 (days 1 and 8 every 21 days) plus best supportive care (BSC) or BSC alone...
September 18, 2020: Clinical Lung Cancer
Alberto Aiolfi, Mario Nosotti, Giancarlo Micheletto, Desmond Khor, Gianluca Bonitta, Carolina Perali, Jacopo Marin, Tullio Biraghi, Davide Bona
BACKGROUND: Although minimally invasive lobectomy has gained worldwide interest, there has been debate on perioperative and oncological outcomes. The purpose of this study was to compare outcomes among open lobectomy, video-assisted thoracic surgery lobectomy, and robotic lobectomy. METHODS: PubMed, EMBASE, and Web of Science databases were consulted. A fully Bayesian network meta-analysis was performed. RESULTS: Thirty-four studies (183,426 patients) were included; 88,865 (48...
October 20, 2020: Surgery
Rika Fujino, Yoshihito Masuoka, Taro Mashiko, Akira Nakano, Kenichi Hirabayashi, Toshio Nakagohri
BACKGROUND: Intraductal papillary neoplasm of the bile duct (IPNB) is considered a pre-cancerous biliary lesion and/or an early cancer lesion, although its classification remains unclear. The 2019 revised edition of the World Health Organization Classification of Tumors of the Digestive System proposed type 1 and type 2 as new classification categories, and meta-analyses and/or multi-center cohort studies are beginning to be reported. However, treatment for IPNB recurrence and metastasis remains unclear...
October 23, 2020: World Journal of Surgical Oncology
Qi Dong, Chenkang Zhou, Haodong Ren, Zhijian Zhang, Feng Cheng, Zhenkai Xiong, Chuantao Chen, Jianke Yang, Jiguang Gao, Yao Zhang, Lei Xu, Jian Fang, Yuxiang Cao, Huijun Wei, Zhihao Wu
BACKGROUND: Metabolic reprogramming contributes significantly to tumor development and is tightly linked to drug resistance. The chemotherapeutic agent etoposide (VP-16) has been used clinically in the treatment of lung cancer but possess different sensitivity and efficacy towards SCLC and NSCLC. Here, we assessed the impact of etoposide on glycolytic metabolism in SCLC and NSCLC cell lines and investigated the role of metabolic rewiring in mediating etoposide resistance. METHODS: glycolytic differences of drug-treated cancer cells were determined by extracellular acidification rate (ECAR), glucose consumption, lactate production and western blot...
October 23, 2020: Cell Communication and Signaling: CCS
Chuanmin Zhang, Yinan Zhao, Enxia Zhang, Meilin Jiang, Defu Zhi, Huiying Chen, Shaohui Cui, Yuhong Zhen, Jingnan Cui, Shubiao Zhang
The combination of chemotherapeutic drug paclitaxel (PTX) and VEGF siRNA could inhibit cancer development with synergistic efficacy. However, efficient and safe delivery systems with high encapsulation efficiency of PTX and a long-time release of drugs are urgently needed. In this study, novel nanoparticles (PTX/siRNA/FALS) were constructed by using tripeptide lipid (L), sucrose laurate (S), and folate-PEG2000 -DSPE (FA) to co-deliver PTX and siRNA. The cancer cell targeting nanoparticle carrier (PTX/siRNA/FALS) showed anticipated PTX encapsulation efficiency, siRNA retardation ability, improved cell uptake and sustained and controlled drug release...
December 2020: Drug Delivery
Ramon Andrade de Mello, Giovanna Araújo Amaral
Lung cancer (LC) is inarguably one of the biggest battles to be fought in the field of oncology, and non-small cell lung cancer accounts for over 85% of all lung cancer cases [...].
October 21, 2020: Journal of Clinical Medicine
Takumi Fujiwara, Tetsu Kobayashi, Taro Yasuma, Corina N D'Alessandro-Gabazza, Masaaki Toda, Hajime Fujimoto, Kentaro Fujiwara, Atsuro Takeshita, Kota Nishihama, Tomohito Okano, Valeria Fridman D'Alessandro, Yoshiyuki Takei, Osamu Hataji, Esteban C Gabazza
Background: Lung cancer is the leading cause of mortality for cancer worldwide. A point mutation in exon 21 of the epidermal growth factor receptor resulting in the substitution of arginine for leucine at position 858 (L858R) is a frequent cause of lung adenocarcinoma. Tyrosine kinase inhibitors are effective for treating patients with lung cancer associated with mutant epidermal growth factor receptors but most tumors become resistant shortly after treatment. The substitution of methionine for threonine at position 790 (T790M) on exon 20 is the most frequently acquired mutation leading to resistance to tyrosine kinase inhibitors...
October 21, 2020: Cancers
Chongxu Zhang, Tengjiao Cui, Renzhi Cai, Medhi Wangpaichitr, Mehdi Mirsaeidi, Andrew V Schally, Robert M Jackson
Growth hormone-releasing hormone (GHRH) is secreted primarily from the hypothalamus, but other tissues, including the lungs, produce it locally. GHRH stimulates the release and secretion of growth hormone (GH) by the pituitary and regulates the production of GH and hepatic insulin-like growth factor-1 (IGF-1). Pituitary-type GHRH-receptors (GHRH-R) are expressed in human lungs, indicating that GHRH or GH could participate in lung development, growth, and repair. GHRH-R antagonists (i.e., synthetic peptides), which we have tested in various models, exert growth-inhibitory effects in lung cancer cells in vitro and in vivo in addition to having anti-inflammatory, anti-oxidative, and pro-apoptotic effects...
October 21, 2020: Cells
Jie Liu, Xiao Han, Lijuan Chen, Dong Han, Xiaoqian Mu, Xiufeng Hu, Hongbo Wu, Huijuan Wu, Wenjing Liu, Yanqiu Zhao
The tumor immune microenvironment (TIME) is an important determinant of cancer prognosis and treatment efficacy. To identify immune-related prognostic biomarkers of lung adenocarcinoma, we used the ESTIMATE algorithm to calculate the immune and stromal scores of 517 lung adenocarcinoma patients from The Cancer Genome Atlas (TCGA). We detected 985 differentially expressed genes (DEGs) between patients with high and low immune and stromal scores, and we analyzed their functions and protein-protein interactions...
October 22, 2020: Aging
Tejpal Gupta, Sarbani Ghosh-Laskar, Jai Prakash Agarwal
The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing worldwide, with over three quarters of cases now diagnosed in low and middle-income countries (LMICs) with resource-constraints. Loco-regional recurrence remains the predominant pattern of failure mandating adequate local therapy for acceptable loco-regional control and survival. There is high-quality evidence that intensification of treatment by either by adding concurrent chemotherapy or by altering radiotherapy (RT) fractionation improves outcomes in the curative-intent management of loco-regionally advanced HNSCC...
October 19, 2020: Oral Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"